SEOUL — Johnson & Johnson has announced final overall survival (OS) data from the Phase 3 PAPILLON study, demonstrating that first-line RYBREVANT® (amivantamab-vmjw) combined with carboplatin-pemetrexed chemotherapy significantly extends life for patients with advanced non-small cell lung cancer (NSCLC) harbouring EGFR exon 20 insertion mutations. Presented at the IASLC 2026 World Conference on Lung Cancer, the trial revealed a median OS of 34.3 months for the combination therapy compared to 27.9 months for chemotherapy alone. This nearly three-year survival benchmark represents the longest reported median OS in this historically challenging patient population, extending survival by more than six months despite 76 per cent of control-arm patients crossing over to second-line RYBREVANT following disease progression.

The milestone results offer new hope for a lung cancer subset that accounts for roughly 12 per cent of all EGFR mutations and carries a dismal five-year survival rate of just 8 per cent. RYBREVANT—a first-in-class bispecific antibody designed to target both EGFR and MET pathways while engaging the immune system—showed sustained benefit, extending progression-free survival through second progression (PFS2) by over 10 months (28.3 vs 17.5 months). Adjusting for patient crossover, the combination reduced the risk of death by 43 per cent compared to chemotherapy alone. Featuring a safety profile consistent with previous findings, the treatment regimen establishes a robust new benchmark, giving patients with historically poor prognoses a significantly longer, higher-quality survival outcome.

This summary is based on a press release issued by Johnson & Johnson.